June 15, 2018 / 6:45 AM / 3 months ago

BRIEF-Novartis AG Says Real-World Data Study Concludes Jakavi Cuts Death Risk

June 15 (Reuters) - Novartis AG:

* SAYS STUDY OF REAL-WORLD DATA CONCLUDES JAKAVI IS ASSOCIATED WITH A REDUCTION IN RISK OF DEATH AND DANGEROUS BLOOD CLOTS FOR PATIENTS WITH RARE BLOOD CANCER

* NOVARTIS AG SAYS ‍COMPARISON OF JAKAVI (RUXOLITINIB) VS. BEST AVAILABLE THERAPY PRESENTED AT EHA SUGGESTS REDUCED RISK OF DEATH IN PATIENTS WITH INADEQUATELY CONTROLLED POLYCYTHEMIA VERA (PV)

* NOVARTIS AG SAYS ‍ADDITIONAL DATA AT EHA SUGGESTS EARLIER TREATMENT WITH JAKAVI MAY LEAD TO IMPROVED OUTCOMES FOR PATIENTS WITH MYELOFIBROSIS (MF) Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below